GEVA Documents déposés auprès de la SEC - Synageva Biopharma Corp- Rapport annuel, procuration, prospectus

Statistiques de base

CIK

911326

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Synageva Biopharma Corp

SEC Filings (Chronological Order)

Cette page fournit une liste complète et chronologique des documents déposés auprès de la SEC, à l'exclusion des documents relatifs à la participation que nous fournissons ailleurs.

July 6, 2015	15-12G	GEVA FORM 15 Form 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-23155 ALEXION PHARMA LLC (successor in interest to SYNAGEVA BIOP
June 24, 2015	SC 13D/A	GEVA / Synageva Biopharma Corp / Baker Brothers Advisors LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 13)* Under the Securities Exchange Act of 1934 Synageva BioPharma Corp. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 896263100 (CUSIP Number) Alexander A. Toohey Chief Financial Officer Baker Bros. Advisors LP 667 Madison Avenue, 21st Floor New York, NY 100
June 23, 2015	S-8 POS	GEVA S-8 POS S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	S-8 POS	GEVA S-8 POS S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	S-8 POS	GEVA S-8 POS S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	S-8 POS	GEVA S-8 POS S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	S-8 POS	GEVA S-8 POS S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	S-8 POS	GEVA S-8 POS S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	S-8 POS	GEVA S-8 POS S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	S-8 POS	GEVA S-8 POS S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	S-8 POS	GEVA S-8 POS S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	S-8 POS	GEVA S-8 POS S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	S-8 POS	GEVA S-8 POS S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	S-8 POS	GEVA S-8 POS S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	S-8 POS	GEVA S-8 POS S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	S-8 POS	GEVA S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	S-8 POS	GEVA S-8 POS S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	S-8 POS	GEVA S-8 POS S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	S-8 POS	GEVA S-8 POS S-8 POS As filed with the Securities and Exchange Commission on June 23, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2015	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) June 19, 2015 ALEXION PHARMA LLC (successor in interest to SYNAGEVA BIOPHARMA CORP.) (Exact name of registrant as specified in charter) Delaware 0-23155 56-1808663 (State or O
June 22, 2015	425	Alexion Pharmaceuticals 425 (Prospectus) Filed by Alexion Pharmaceuticals, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 of the Securities Exchange Act of 1934 Subject Company: Synageva BioPharma Corp. Commission File No.: 0-23155 Alexion Accepts Shares of Synageva BioPharma Corp. Tendered Into Exchange Offer CHESHIRE, Conn.—June 22, 2015—Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) an
June 22, 2015	SC 14D9/A	GEVA AMENDMENT NO.6 TO SCHEDULE 14D-9 Amendment No.6 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6) SYNAGEVA BIOPHARMA CORP. (Name of Subject Company) SYNAGEVA BIOPHARMA CORP. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title o
June 22, 2015	EX-99.(A)(5)(I)	Alexion Accepts Shares of Synageva BioPharma Corp. Tendered Into Exchange Offer Exhibit (a)(5)(I) Alexion Accepts Shares of Synageva BioPharma Corp. Tendered Into Exchange Offer CHESHIRE, Conn.?June 22, 2015?Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that it has accepted for exchange all 21,021,124 shares validly tendered into the previously announced exchange offer by a wholly owned subsidiary of Alexion to acquire all of the outstanding shares of Synageva
June 22, 2015	SC TO-T/A	Alexion Pharmaceuticals AMENDMENT NO. 3 TO SCHEDULE TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO AMENDMENT NO. 3 (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Synageva BioPharma Corp. (Names of Subject Company) PULSAR MERGER SUB INC. (Offeror) ALEXION PHARMACEUTICALS, INC. (Parent of Offeror) (Names of Filing Persons) COMMON STOCK, $0.001
June 12, 2015	425	GEVA 425 (Prospectus) 425 Filed by Synageva BioPharma Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Synageva BioPharma Corp. Commission File No.: 0-23155 Dear Synageva Employee, Consistent with Synageva?s practice of granting annual equity awards, on June 6, 2015 the Board of Directors granted Restricted St
June 12, 2015	SC 14D9/A	GEVA AMENDMENT NO.5 TO SCHEDULE 14D-9 Amendment No.5 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) SYNAGEVA BIOPHARMA CORP. (Name of Subject Company) SYNAGEVA BIOPHARMA CORP. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title o
June 12, 2015	EX-99.(A)(1)(H)	Dear Synageva Employee, Email to Synageva Employees Exhibit (a)(1)(H) Dear Synageva Employee, Consistent with Synageva?s practice of granting annual equity awards, on June 6, 2015 the Board of Directors granted Restricted Stock Units or RSUs (2015 RSU Awards) to most employees who were employed before January 1, 2015.
June 11, 2015	425	GEVA 425 (Prospectus) 425 Filed by Synageva BioPharma Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Synageva BioPharma Corp. Commission File No.: 0-23155 Dear Synageva Employees, Quite a few of you have asked for clarification on how to calculate the value of your Synageva stock options upon the close of th
June 11, 2015	EX-99.(A)(1)(G)	Attached Spreadsheet Number of Options Strike Price Value Over Strike Price Share Equivalent Ratio Amount of GEVA Equivalents Cash ($115 * equivalents) ALXN Shares (.6581 conversion ratio) FMV of Shares Total Pre-Tax Consideration A 200 $ 75.00 $ 155 EX-99.(A)(1)(G) 2 d931600dex99a1g.htm LETTER TO SYNAGEVA EMPLOYEES Exhibit (a)(1)(G) Dear Synageva Employees, Quite a few of you have asked for clarification on how to calculate the value of your Synageva stock options upon the close of the merger with Alexion and how much cash and Alexion stock you will receive for that value. The attached spreadsheet was developed as an example to illustrate the
June 11, 2015	SC 14D9/A	GEVA AMENDMENT NO.4 TO SCHEDULE 14D-9 Amendment No.4 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) SYNAGEVA BIOPHARMA CORP. (Name of Subject Company) SYNAGEVA BIOPHARMA CORP. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title o
June 10, 2015	EX-99.(A) (1) (F)	Alexion and Synageva Integration Frequently Asked Questions & Answers ? General HR EX-99.(a) (1) (F) Exhibit (a)(1)(F) Alexion and Synageva Integration Frequently Asked Questions & Answers ? General HR This list of frequently asked questions and answers is intended to assist with questions that you may have relating to the announced transaction between Synageva and Alexion. If you are unable to find the answer to your question in this document, please contact your local HR Repre
June 10, 2015	425	Alexion Pharmaceuticals 425 (Prospectus) Filed by Alexion Pharmaceuticals, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Synageva BioPharma Corp. Commission File No.: 0-23155 The following FAQ was distributed to employees of Synageva BioPharma Corp. Alexion and Synageva Integration Frequently Asked Questions & Answers ? General H
June 10, 2015	425	GEVA 425 (Prospectus) 425 Filed by Synageva BioPharma Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Synageva BioPharma Corp. Commission File No.: 0-23155 Alexion and Synageva Integration Frequently Asked Questions & Answers ? General HR This list of frequently asked questions and answers is intended to assi
June 10, 2015	SC 14D9/A	GEVA AMENDMENT NO.3 TO SCHEDULE 14D-9 Amendment No.3 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) SYNAGEVA BIOPHARMA CORP. (Name of Subject Company) SYNAGEVA BIOPHARMA CORP. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title o
June 9, 2015	SC TO-T/A	Alexion Pharmaceuticals AMENDMENT NO. 2 TO SCHEDULE TO-T t1501315-sctota - none - 2.3762376s ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE TO AMENDMENT NO. 2 (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ? Synageva BioPharma Corp. (Names of Subject Company) ? PULSAR MERGER SUB INC. (Offeror) ? ALEXION PHARMACEUTICALS, INC. (Parent of Offero
June 8, 2015	SC 14D9/A	GEVA AMENDMENT NO.2 TO SCHEDULE 14D-9 Amendment No.2 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) SYNAGEVA BIOPHARMA CORP. (Name of Subject Company) SYNAGEVA BIOPHARMA CORP. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title o
June 8, 2015	CORRESP	GEVA ESP June 8, 2015 VIA EDGAR Nicholas P. Panos Senior Special Counsel Office of Mergers & Acquisitions United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Synageva BioPharma Corp. Schedule 14D-9 Filed May 22, 2015 File No. 005-52299 Dear Mr. Panos: Synageva BioPharma Corp. (the ?Company?) is submitting this letter in response to t
June 5, 2015	SC 13G/A	GEVA / Synageva Biopharma Corp / COLUMBIA WANGER ASSET MANAGEMENT LLC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* SYNAGEVA BIOPHARMA CORP. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 87159A103 (CUSIP Number) May 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule
June 5, 2015	425	Alexion Pharmaceuticals 425 (Prospectus) The following webpages appear on Alexion Pharmaceuticals, Inc.?s internal website Filed by Alexion Pharmaceuticals, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14a - 12 of the Securities Exchange Act of 1934 Subject Company: Synageva BioPharma Corp. Commission File No.: 0 - 23155 A View to Synageva Integration Planning Dan Bazarko, Vice President, A
June 1, 2015	EX-99.(A)(5)(G)	Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexion’s Pending Acquisition of Synageva Exhibit (a)(5)(G) Friday, May 29, 2015 4:20 pm EDT Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexion?s Pending Acquisition of Synageva CHESHIRE, Conn.
June 1, 2015	425	Alexion Pharmaceuticals 425 (Prospectus) Filed by Alexion Pharmaceuticals, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Synageva BioPharma Corp. Commission File No.: 0-23155 Friday, May 29, 2015 4:20 pm EDT Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexion’s Pending Acquisition of Sy
June 1, 2015	EX-99.(A)(5)(C)	Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexion’s Pending Acquisition of Synageva EX-99.(A)(5)(C) 2 d931600dex99a5c.htm JOINT PRESS RELEASE Exhibit (a)(5)(C) Friday, May 29, 2015 4:20 pm EDT Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexion’s Pending Acquisition of Synageva CHESHIRE, Conn. & LEXINGTON, Mass.—(BUSINESS WIRE)—Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) and Synageva BioPharma Corp. (Nasdaq:GEVA) today announced that th
June 1, 2015	425	GEVA 425 (Prospectus) 425 Filed by Synageva BioPharma Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Synageva BioPharma Corp. Commission File No.: 0-23155 Friday, May 29, 2015 4:20 pm EDT Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexion?s Pending Acquisition of
June 1, 2015	SC 14D9/A	GEVA AMENDMENT NO.1 TO SCHEDULE 14D-9 Amendment No.1 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) SYNAGEVA BIOPHARMA CORP. (Name of Subject Company) SYNAGEVA BIOPHARMA CORP. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title o
June 1, 2015	SC TO-T/A	Alexion Pharmaceuticals AMENDMENT NO. 1 TO SCHEDULE TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO AMENDMENT NO. 1 (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Synageva BioPharma Corp. (Names of Subject Company) PULSAR MERGER SUB INC. (Offeror) ALEXION PHARMACEUTICALS, INC. (Parent of Offeror) (Names of Filing Persons) COMMON STOCK, $0.001
May 22, 2015	SC TO-T	Alexion Pharmaceuticals SCHEDULE TO t1501057-scto - none - 2.3362336s ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ? Synageva BioPharma Corp. (Names of Subject Company) ? PULSAR MERGER SUB INC. (Offeror) ? ALEXION PHARMACEUTICALS, INC. (Parent of Offeror) ? (Names of Fil
May 22, 2015	EX-99.(A)(5)(F)	EX-99.(A)(5)(F) Exhibit (a)(5)(F) A registration statement relating to the securities proposed to be issued in the Offer (as defined below) has been filed with the U.
May 22, 2015	EX-99.(E)(10)	Amendment No. 1 to the Synageva BioPharma Corp. Employee Stock Purchase Plan EX-99.(e)(10) Exhibit (e)(10) Amendment No. 1 to the Synageva BioPharma Corp. Employee Stock Purchase Plan WHEREAS, Synageva BioPharma Corp. (the ?Company?) has adopted and maintains the Synageva BioPharma Corp. Employee Stock Purchase Plan (the ?Plan?); and WHEREAS, the Board of Directors of the Company desires to amend the Plan as set forth herein. NOW, THEREFORE, pursuant to Section 18 of the P
May 22, 2015	SC 14D9	GEVA SC 14D9 SC 14D9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 SYNAGEVA BIOPHARMA CORP. (Name of Subject Company) SYNAGEVA BIOPHARMA CORP. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 87159A103 (CUSIP Num
May 22, 2015	EX-99.(E)(2)	BENEFICIAL OWNERSHIP OF COMMON STOCK EX-99.(e)(2) Exhibit (e)(2) Excerpts from Synageva BioPharma Corp.?s Definitive Proxy Statement on Schedule 14A related to the 2015 Annual Meeting of Stockholders as filed with the Securities and Exchange Commission on April 28, 2015. BENEFICIAL OWNERSHIP OF COMMON STOCK The following table sets forth certain information as of April 10, 2015 (except as otherwise noted) regarding the beneficial own
May 11, 2015	425	Alexion Pharmaceuticals 425 (Prospectus) Global Town Hall David Hallal Chief Executive Officer, Alexion May 11, 2015 Filed by Alexion Pharmaceuticals, Inc.
May 11, 2015	425	GEVA 425 (Prospectus) Filed by Synageva BioPharma Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Synageva BioPharma Corp. Commission File No.: 0-23155 To All Synageva Employees, Ive asked Sanj to share this letter with all of you so that I could personally tell you how excited we are at Alexion about Wednes
May 11, 2015	425	Alexion Pharmaceuticals 425 (Prospectus) Filed by Alexion Pharmaceuticals, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Synageva BioPharma Corp. Commission File No.: 0-23155 A recording of a town hall meeting given by CEO David Hallal to Alexion employees was made available on Alexion's intranet on May 11, 2015. * * * Alexion To
May 11, 2015	SC14D9C	GEVA SC14D9C SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 SYNAGEVA BIOPHARMA CORP. (Name of Subject Company) SYNAGEVA BIOPHARMA CORP. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 87159A103 (CUSIP Num
May 7, 2015	SC 13D/A	GEVA / Synageva Biopharma Corp / Baker Brothers Advisors LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 12)* Under the Securities Exchange Act of 1934 Synageva BioPharma Corp. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 896263100 (CUSIP Number) Alexander A. Toohey Chief Financial Officer Baker Bros. Advisors LP 667 Madison Avenue, 21st Floor New York, NY 100
May 7, 2015	EX-99.1	VOTING AND SUPPORT AGREEMENT Exhibit 1 EXECUTION VERSION VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of May 5, 2015, is entered into by and among Alexion Pharmaceuticals, Inc.
May 6, 2015	EX-3.1	SECOND THIRD AMENDED AND RESTATED BYLAWS TRIMERIS, INC. SYNAGEVA BIOPHARMA CORP. ARTICLE 1 – STOCKHOLDERS EX-3.1 Exhibit 3.1 SECOND THIRD AMENDED AND RESTATED BYLAWS OF TRIMERIS, INC. SYNAGEVA BIOPHARMA CORP. ARTICLE 1 ? STOCKHOLDERS 1.1 Place of Meeting. All meetings of stockholders shall be held at such place within or without the State of Delaware as may be designated from time to time by the Board of Directors or the President or, if not so designated, at the registered office of the corporation.
May 6, 2015	EX-2.1	AGREEMENT AND PLAN OF REORGANIZATION by and among ALEXION PHARMACEUTICALS, INC., PULSAR MERGER SUB INC., GALAXY MERGER SUB LLC, SYNAGEVA BIOPHARMA CORP. Dated as of May 5, 2015 TABLE OF CONTENTS Page ARTICLE I. THE OFFER Section 1.1 The Offer 2 Secti EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF REORGANIZATION by and among ALEXION PHARMACEUTICALS, INC., PULSAR MERGER SUB INC., GALAXY MERGER SUB LLC, and SYNAGEVA BIOPHARMA CORP. Dated as of May 5, 2015 TABLE OF CONTENTS Page ARTICLE I. THE OFFER Section 1.1 The Offer 2 Section 1.2 Schedule TO; Offer Documents; Offer Form S-4 6 Section 1.3 Company Actions 8 ARTICLE II. THE MERGERS S
May 6, 2015	EX-4.1	VOTING AND SUPPORT AGREEMENT Exhibit 4.1 EXECUTION VERSION VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of May 5, 2015, is entered into by and among Alexion Pharmaceuticals, Inc. a Delaware corporation (“Parent”), Pulsar Merger Sub Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”), and each of the persons set forth on Schedule A hereto (eac
May 6, 2015	EX-2.1	AGREEMENT AND PLAN OF REORGANIZATION by and among ALEXION PHARMACEUTICALS, INC., PULSAR MERGER SUB INC., GALAXY MERGER SUB LLC, SYNAGEVA BIOPHARMA CORP. Dated as of May 5, 2015 TABLE OF CONTENTS Page ARTICLE I. THE OFFER Section 1.1 The Offer 2 Secti EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF REORGANIZATION by and among ALEXION PHARMACEUTICALS, INC., PULSAR MERGER SUB INC., GALAXY MERGER SUB LLC, and SYNAGEVA BIOPHARMA CORP. Dated as of May 5, 2015 TABLE OF CONTENTS Page ARTICLE I. THE OFFER Section 1.1 The Offer 2 Section 1.2 Schedule TO; Offer Documents; Offer Form S-4 6 Section 1.3 Company Actions 8 ARTICLE II. THE MERGERS S
May 6, 2015	EX-2.1	AGREEMENT AND PLAN OF REORGANIZATION by and among ALEXION PHARMACEUTICALS, INC., PULSAR MERGER SUB INC., GALAXY MERGER SUB LLC, SYNAGEVA BIOPHARMA CORP. Dated as of May 5, 2015 TABLE OF CONTENTS Exhibit 2.1 AGREEMENT AND PLAN OF REORGANIZATION by and among ALEXION PHARMACEUTICALS, INC., PULSAR MERGER SUB INC., GALAXY MERGER SUB LLC, and SYNAGEVA BIOPHARMA CORP. Dated as of May 5, 2015 TABLE OF CONTENTS TABLE OF CONTENTS Page Article I. THE OFFER Section 1.1 The Offer 2 Section 1.2 Schedule TO; Offer Documents; Offer Form S-4 4 Section 1.3 Company Actions 6 Article II. TH
May 6, 2015	425	Alexion Pharmaceuticals 425 (Prospectus) Filed by Alexion Pharmaceuticals, , Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14d-2 of the Securities Exchange Act of 1934 Subject Company: Synageva BioPharma Corp. Commission File No.: 0-23155 Alexion Agrees to Acquire Synageva BioPharma A Message from David Hallal, Chief Executive Officer Dear Colleagues: I am very excited to share with you toda
May 6, 2015	EX-99.1	Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases -- Expands Alexion’s metabolic franchise with the addition of Kanuma™ (sebelipase a Exhibit 99.1 Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases - Expands Alexion?s metabolic franchise with the addition of Kanuma? (sebelipase alfa) for LAL Deficiency (LAL-D) ? - Launches of Kanuma and Alexion?s Strensiq? (asfotase alfa) expected in 2015 ? - Creates the most robus
May 6, 2015	EX-4.2	VOTING AND SUPPORT AGREEMENT Exhibit 4.2 EXECUTION VERSION VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of May 5, 2015, is entered into by and among Alexion Pharmaceuticals, Inc. a Delaware corporation (“Parent”), Pulsar Merger Sub Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”), and Thomas J. Tisch (the “Stockholder”). All terms used but
May 6, 2015	425	GEVA FORM 8-K (Prospectus) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) May 5, 2015 SYNAGEVA BIOPHARMA CORP. (Exact name of registrant as specified in charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commission
May 6, 2015	425	Alexion Pharmaceuticals 425 (Prospectus) Alexion: Global Leader in Rare Diseases Filed by Alexion Pharmaceuticals, , Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14d - 2 of the Securities Exchange Act of 1934 Subject Company: Synageva BioPharma Corp. Commission File No.: 0 - 23155 2 This communication includes statements that may be forward - looking statements. The words ?believe,? ?expect
May 6, 2015	425	Merger Prospectus - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2015 ALEXION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-27756 13-3648318 (State or other jurisdiction of incorporation) (Commissi
May 6, 2015	SC14D9C	GEVA SC14D9C SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 SYNAGEVA BIOPHARMA CORP. (Name of Subject Company) SYNAGEVA BIOPHARMA CORP. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 87159A103 (CUSIP Num
May 6, 2015	EX-99.1	Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases — Expands Alexion’s metabolic franchise with the addition of Kanuma™ (sebelipase al EX-99.1 Exhibit 99.1 Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases ? Expands Alexion?s metabolic franchise with the addition of Kanuma? (sebelipase alfa) for LAL Deficiency (LAL-D) ? ? Launches of Kanuma and Alexion?s Strensiq? (asfotase alfa) expected in 2015 ? ? Creates the mo
May 6, 2015	EX-3.1	SECOND THIRD AMENDED AND RESTATED BYLAWS TRIMERIS, INC. SYNAGEVA BIOPHARMA CORP. ARTICLE 1 – STOCKHOLDERS EX-3.1 Exhibit 3.1 SECOND THIRD AMENDED AND RESTATED BYLAWS OF TRIMERIS, INC. SYNAGEVA BIOPHARMA CORP. ARTICLE 1 ? STOCKHOLDERS 1.1 Place of Meeting. All meetings of stockholders shall be held at such place within or without the State of Delaware as may be designated from time to time by the Board of Directors or the President or, if not so designated, at the registered office of the corporation.
May 6, 2015	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) May 5, 2015 SYNAGEVA BIOPHARMA CORP. (Exact name of registrant as specified in charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commission File Numb
May 6, 2015	EX-99.1	Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases Expands Alexions metabolic franchise with the addition of Kanuma (sebelipase al EX-99.1 Exhibit 99.1 Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases ? Expands Alexion?s metabolic franchise with the addition of Kanuma? (sebelipase alfa) for LAL Deficiency (LAL-D) ? ? Launches of Kanuma and Alexion?s Strensiq? (asfotase alfa) expected in 2015 ? ? Creates the mo
April 30, 2015	10-Q	GEVA FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 30, 2015	EX-10.3	Synageva BioPharma Corp. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company’s 2014 Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Grant of Restricted Stock Unit Award: 3. Maximum Number EX-10.3 Exhibit 10.3 Restricted Stock Unit No. Synageva BioPharma Corp. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company’s 2014 Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Grant of Restricted Stock Unit Award: 3. Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vesting of Award: This Restricted Stock Unit Award
April 30, 2015	EX-10.1	COMMERCIAL SUPPLY AGREEMENT EX-10.1 Exhibit 10.1 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. Fujifilm ? Synageva Agreement EXECUTION COPY COMMERCIAL SUPPLY AGREEMENT This Commercial Supply Agreement (this ?Agreement?) dated January 28, 2015 (the ?Effective Date?) between Synageva BioPharma
April 30, 2015	EX-10.2	Manufacturing Services Agreement February 4th, 2015 EX-10.2 Exhibit 10.2 [] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. Manufacturing Services Agreement Manufacturing Services Agreement February 4th, 2015 [] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted ver
April 29, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d918898d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 29, 2015 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorpo
April 29, 2015	EX-99.1	SYNAGEVA BIOPHARMA REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS AND PROVIDES GENERAL BUSINESS UPDATES EX-99.1 Exhibit 99.1 SYNAGEVA BIOPHARMA REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS AND PROVIDES GENERAL BUSINESS UPDATES LEXINGTON, Mass., April 29, 2015 ? Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today reported first quarter 2015 financial results and provided other business updates. ?This is an exciting time for Sy
April 28, 2015	DEF 14A	GEVA NOTICE & PROXY STATEMENT Notice & Proxy Statement SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.
April 14, 2015	PRE 14A	GEVA PRELIMINARY NOTICE & PROXY STATEMENT Preliminary Notice & Proxy Statement SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240.
February 26, 2015	EX-10.19	Synageva BioPharma Corp. Stock Option Grant Notice Stock Option Grant under the Company’s 2014 Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Option Grant: 3. Type of Grant: 4. Maximum Number of Shares for which this Option is e Exhibit 10.19 Synageva BioPharma Corp. Stock Option Grant Notice Stock Option Grant under the Company’s 2014 Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Option Grant: 3. Type of Grant: 4. Maximum Number of Shares for which this Option is exercisable: 5. Exercise (purchase) price per share: 6. Option Expiration Date: 7. Vesting Start Date: 8. Vesting Schedule: This Option s
February 26, 2015	EX-99.1	SYNAGEVA BIOPHARMA REPORTS 2014 FULL YEAR FINANCIAL RESULTS -Strengthened balance sheet enables focus on both Kanuma™ (sebelipase alfa) and multiple pipeline programs- EX-99.1 Exhibit 99.1 SYNAGEVA BIOPHARMA REPORTS 2014 FULL YEAR FINANCIAL RESULTS -Strengthened balance sheet enables focus on both Kanuma™ (sebelipase alfa) and multiple pipeline programs- LEXINGTON, Mass., February 26, 2015 — Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today reported 2014 full year financial results and
February 26, 2015	10-K	Annual Report - FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified
February 26, 2015	EX-21.1	Jurisdiction of Organization Exhibit 21.1 Subsidiary Jurisdiction of Organization Abbey BioPharma Corp. Delaware Synageva BioPharma Ltd United Kingdom Synageva BioPharma B.V. Netherlands Synageva BioPharma Germany GmbH Germany Synageva BioPharma GmbH Switzerland Synageva BioPharma Japan KK Japan Synageva BioPharma Luxembourg S.a.r.l. Luxembourg Synageva BioPharma SAS France Synageva BioPharma S de RL de CV Mexico Synageva Bio
February 26, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d882190d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 26, 2015 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of
February 11, 2015	EX-99.1	EXHIBIT 99.1 - JOINT FILING AGREEMENT EX-99.1 Exhibit 99.1 EXHIBIT 99.1 - JOINT FILING AGREEMENT The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the
February 11, 2015	SC 13G/A	GEVA / Synageva Biopharma Corp / COLUMBIA WANGER ASSET MANAGEMENT LLC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* SYNAGEVA BIOPHARMA CORP. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 87159A103 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the Rule pursuant to which this Sch
February 9, 2015	8-K	Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 4, 2015 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commi
February 2, 2015	8-K	Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 28, 2015 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commi
January 9, 2015	SC 13D/A	GEVA / Synageva Biopharma Corp / BAKER JULIAN - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 11)* Under the Securities Exchange Act of 1934 Synageva BioPharma Corp. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 896263100 (CUSIP Number) Alexander A. Toohey Chief Financial Officer Baker Bros. Advisors LP 667 Madison Avenue, 21st Floor New York, NY 100
January 7, 2015	EX-99.2	SYNAGEVA BIOPHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK EX-99.2 Exhibit 99.2 SYNAGEVA BIOPHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK LEXINGTON, Mass., January 6, 2015 — Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the pricing of its previously announced underwritten public offering of common stock consisting of 3.0 million shares at $94.19 per sh
January 7, 2015	424B5	CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0. 424(B)(5) Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0.
January 7, 2015	EX-99.1	SYNAGEVA BIOPHARMA ANNOUNCES A 2.5 MILLION SHARE PROPOSED PUBLIC OFFERING OF ITS COMMON STOCK EX-99.1 Exhibit 99.1 SYNAGEVA BIOPHARMA ANNOUNCES A 2.5 MILLION SHARE PROPOSED PUBLIC OFFERING OF ITS COMMON STOCK LEXINGTON, Mass., January 5, 2015 — Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced that it intends to offer for sale 2.50 million shares of its common stock in an underwritten public offering. In
January 7, 2015	EX-99.3	SYNAGEVA BIOPHARMA ANNOUNCES NEW PIPELINE PROGRAMS AND OTHER COMPANY PROGRESS EX-99.3 Exhibit 99.3 SYNAGEVA BIOPHARMA ANNOUNCES NEW PIPELINE PROGRAMS AND OTHER COMPANY PROGRESS LEXINGTON, Mass., January 5, 2015 — Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today new pipeline programs and other company progress. “We are building a global, generational company that will continue to make a m
January 7, 2015	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 5, 2015 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commission
January 7, 2015	EX-1.1	3,000,000 Shares Synageva BioPharma Corp. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 3,000,000 Shares Synageva BioPharma Corp. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT January 6, 2015 January 6, 2015 Goldman, Sachs & Co. J.P. Morgan Securities LLC As Representatives of the several Underwriters listed in Schedule I c/o Goldman, Sachs & Co. 200 West Street New York, New York 10282 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, N
January 5, 2015	424B5	Subject to completion, dated January 5, 2015 424(B)(5) Table of Contents Filed pursuant to Rule 424(b)(5) Registration No.: 333-185856 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale
October 30, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
October 30, 2014	EX-99.1	SYNAGEVA BIOPHARMA REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 SYNAGEVA BIOPHARMA REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS LEXINGTON, Mass., October 30, 2014 — Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today third quarter 2014 financial results, and provided other business updates. Sebelipase alfa for LAL Deficiency The company recently started th
October 30, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 30, 2014 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commission
September 22, 2014	EX-99.1	SYNAGEVA BIOPHARMA APPOINTS ROBERT BAZEMORE AS CHIEF OPERATING OFFICER -Focus on Commercial Readiness and Global Operations- EX-99.1 Exhibit 99.1 SYNAGEVA BIOPHARMA APPOINTS ROBERT BAZEMORE AS CHIEF OPERATING OFFICER -Focus on Commercial Readiness and Global Operations- LEXINGTON, Mass., September 22, 2014 — Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders announced today the appointment of Robert Bazemore as Chief Operating Officer. Repo
September 22, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 22, 2014 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commissi
September 22, 2014	EX-10.1	EMPLOYMENT AGREEMENT EX-10.1 2 d792981dex101.htm EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into by and between Synageva BioPharma Corp. (the “Company”), a Delaware corporation with its principal place of business at 33 Hayden Ave, Lexington, Massachusetts, and Robert Bazemore of 350 South River Rd, E3, New Hope, PA (the “Executive”), effective as of Septe
September 9, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 3, 2014 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Comm
July 31, 2014	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-23155 SYNAGEVA
July 30, 2014	EX-99.1	SYNAGEVA BIOPHARMA™ REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 SYNAGEVA BIOPHARMA™ REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS LEXINGTON, Mass., July 30, 2014 — Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today reported second quarter 2014 financial results, and provided other business updates. Second Quarter 2014 Financial Results For the quarter e
July 30, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 30, 2014 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commissi
June 30, 2014	EX-99.1	SYNAGEVA BIOPHARMA™ REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LAL DEFICIENCY Phase 3 Study Meets Primary Endpoint and Six Secondary Endpoints Across Multiple Disease-Related Abnormalities Conf EX-99.1 Exhibit 99.1 SYNAGEVA BIOPHARMA™ REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LAL DEFICIENCY Phase 3 Study Meets Primary Endpoint and Six Secondary Endpoints Across Multiple Disease-Related Abnormalities Conference Call and Webcast to be Held Today at 4:30 p.m. EDT LEXINGTON, Mass., June 30, 2014 — Synageva BioPharma Corp. (Synageva) (
June 30, 2014	8-K	Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 30, 2014 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commissi
June 26, 2014	S-8	- FORM S-8 Form S-8 As filed with the Securities and Exchange Commission on June 26, 2014 Registration No.
June 9, 2014	EX-10.1	SYNAGEVA BIOPHARMA CORP. 2014 EQUITY INCENTIVE PLAN EX-10.1 Exhibit 10.1 SYNAGEVA BIOPHARMA CORP. 2014 EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Synageva BioPharma Corp. 2014 Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which c
June 9, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 4, 2014 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commission Fil
May 20, 2014	DEFA14A	- DEFA14A DEFA14A 1 d729579ddefa14a.htm DEFA14A SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Addi
May 15, 2014	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 15, 2014 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commissio
May 15, 2014	424B7	CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common Stock, par value $0.001 pe 424B7 Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common Stock, par value $0.
May 1, 2014	EX-10.1	FIRST AMENDMENT TO LEASE EX-10.1 EXHIBIT 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE dated as of this 20 day of February, 2014 by and between THE TRUSTEES OF HAYDEN OFFICE TRUST under Declaration of Trust dated August 24, 1977, as amended (“Landlord”) and SYNAGEVA BIOPHARMA CORP., a Delaware corporation (“Tenant”). RECITALS By Lease dated January 15, 2013 (the “Lease”), Landlord did lease to Tenant, and Te
May 1, 2014	EX-10.2	REGISTRATION RIGHTS AGREEMENT Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of May 1, 2014, by and between Synageva BioPharma Corp., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement
May 1, 2014	10-Q	Quarterly Report - FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 1, 2014	EX-10.3	Amendment to Amended and Restated Information and Registration Rights Agreement Exhibit 10.3 Amendment to Amended and Restated Information and Registration Rights Agreement This Amendment to the Amended and Restated Information and Registration Rights Agreement (this ?Amendment?) is made and entered into as of May 1, 2014 by and among Synageva BioPharma Corp., a Delaware corporation (the ?Company?) and the persons who are signatories to this Amendment (collectively, the ?Inve
April 30, 2014	EX-99.1	SYNAGEVA BIOPHARMA™ REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 SYNAGEVA BIOPHARMA™ REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS LEXINGTON, Mass., April 30, 2014 — Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today reported first quarter 2014 financial results, and provided other business updates. First Quarter 2014 Financial Results For the quarter end
April 30, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 30, 2014 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commiss
April 29, 2014	SC 13D/A	GEVA / Synageva Biopharma Corp / BAKER JULIAN - SC 13D/A Activist Investment SC 13D/A 1 v376338sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 10)* Under the Securities Exchange Act of 1934 Synageva BioPharma Corp. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 896263100 (CUSIP Number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 667 Madis
April 23, 2014	DEF 14A	- NOTICE & PROXY STATEMENT Notice & Proxy Statement SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.
March 10, 2014	SC 13D/A	GEVA / Synageva Biopharma Corp / BAKER JULIAN - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 9)* Under the Securities Exchange Act of 1934 Synageva BioPharma Corp. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 896263100 (CUSIP Number) Alexander A. Toohey Chief Financial Officer Baker Bros. Advisors LP 667 Madison Avenue, 21st Floor New York, NY 1006
March 10, 2014	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the common stock, $0.001 par value, of Synageva BioPharma Corp. is being filed with the Securities and Exchange Commission on behalf of each of them. March 7, 2014 BAKER BROS. ADVISORS LP By: Bake
March 6, 2014	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 4, 2014 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commissi
March 6, 2014	EX-99.2	SYNAGEVA BIOPHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK EX-99.2 Exhibit 99.2 SYNAGEVA BIOPHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK LEXINGTON, Mass., March 5, 2014 — Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the pricing of its previously announced underwritten public offering of common stock consisting of 2.0 million shares at $10
March 6, 2014	424B5	CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0. Final Prospectus Supplement Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0.
March 6, 2014	EX-1.1	2,000,000 Shares Synageva BioPharma Corp. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 2,000,000 Shares Synageva BioPharma Corp. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT March 5, 2014 March 5, 2014 Goldman, Sachs & Co. J.P. Morgan Securities LLC Morgan Stanley & Co. LLC As Representative of the several Underwriters listed in Schedule 1 c/o Goldman, Sachs & Co. 200 West Street New York, New York 10282 c/o J.P. Morgan Securities LLC 383 Madiso
March 6, 2014	EX-99.1	SYNAGEVA BIOPHARMA™ ANNOUNCES A 2.00 MILLION SHARE PROPOSED PUBLIC OFFERING OF ITS COMMON STOCK EX-99.1 Exhibit 99.1 SYNAGEVA BIOPHARMA™ ANNOUNCES A 2.00 MILLION SHARE PROPOSED PUBLIC OFFERING OF ITS COMMON STOCK LEXINGTON, Mass., March 4, 2014 — Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced that it intends to offer for sale 2.00 million shares of its common stock in an underwritten public of
March 4, 2014	EX-10.26	LEASE AGREEMENT RP GATEWAY, LLC, A GEORGIA LIMITED LIABILITY COMPANY SYNAGEVA BIOPHARMA CORP., A DELAWARE CORPORATION LEASE DATED OCTOBER 22, 2013 Exhibit 10.26 [*] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Securities and Exchange Commission. LEASE AGREEMENT BETWEEN RP GATEWAY, LLC, A GEORGIA LIMITED LIABILITY COMPANY “LANDLORD” AND SYNAGEVA BIOPHARMA CORP., A DELAWARE CORPORATION “TENANT” AND FOLLOWING EXHIBITS EXHIBIT “
March 4, 2014	424B5	Subject to completion, dated March 4, 2014 Prospectus Supplement Table of Contents Filed pursuant to Rule 424(b)(5) Registration No.
March 4, 2014	EX-21.1	Jurisdiction of Organization Exhibit 21.1 Subsidiary Jurisdiction of Organization Abbey BioPharma Corp. Delaware Synageva BioPharma Ltd United Kingdom Synageva BioPharma B.V. Netherlands Synageva BioPharma GmbH Switzerland Synageva BioPharma Luxembourg S.a.r.l. Luxembourg Synageva BioPharma SAS France Synageva BioPharma S de RL de CV Mexico Synageva BioPharma S.R.L. Italy Synageva Securities Corp. Massachusetts
March 4, 2014	EX-10.25	AGREEMENT TO LEASE Exhibit 10.25 [*] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Securities and Exchange Commission. AGREEMENT TO LEASE THIS INSTRUMENT IS AN INDENTURE OF LEASE by and between the parties hereinafter named as the Lessor and the Lessee and which relates to the Demised Premises, as th
March 4, 2014	10-K/A	Annual Report - AMENDMENT NO.1 TO FORM 10-K Amendment No.1 to Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 SYNAGEVA BIOPHAR
March 4, 2014	EX-10.6	SECOND AMENDED AND RESTATED LICENSE AGREEMENT Exhibit 10.6 [*] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Securities and Exchange Commission. SECOND AMENDED AND RESTATED LICENSE AGREEMENT THIS SECOND AMENDED AND RESTATED LICENSE AGREEMENT is made and entered into as of December 3, 2013 (the “Second Restatement Effective Dat
March 3, 2014	EX-10.6	SECOND AMENDED AND RESTATED LICENSE AGREEMENT Exhibit 10.6 [*] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Securities and Exchange Commission. SECOND AMENDED AND RESTATED LICENSE AGREEMENT THIS SECOND AMENDED AND RESTATED LICENSE AGREEMENT is made and entered into as of December 3, 2013 (the ?Second Restatement Effective Dat
March 3, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 3, 2014 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commissi
March 3, 2014	EX-21.1	Jurisdiction of Organization Exhibit 21.1 Subsidiary Jurisdiction of Organization Abbey BioPharma Corp. Delaware Synageva BioPharma Ltd United Kingdom Synageva BioPharma B.V. Netherlands Synageva BioPharma GmbH Switzerland Synageva BioPharma Luxembourg S.a.r.l. Luxembourg Synageva BioPharma SAS France Synageva BioPharma S de RL de CV Mexico Synageva BioPharma S.R.L. Italy Synageva Securities Corp. Massachusetts
March 3, 2014	10-K	Annual Report - 10-K 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 3, 2014	EX-10.25	AGREEMENT TO LEASE Exhibit 10.25 [*] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Securities and Exchange Commission. AGREEMENT TO LEASE THIS INSTRUMENT IS AN INDENTURE OF LEASE by and between the parties hereinafter named as the Lessor and the Lessee and which relates to the Demised Premises, as th
March 3, 2014	EX-99.1	SYNAGEVA BIOPHARMA™ REPORTS 2013 FULL YEAR FINANCIAL RESULTS EX-99.1 Exhibit 99.1 SYNAGEVA BIOPHARMA™ REPORTS 2013 FULL YEAR FINANCIAL RESULTS LEXINGTON, Mass., March 3, 2014 — Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today reported 2013 full year financial results and provided 2014 goals, other key objectives and financial guidance. Synageva’s management team will h
March 3, 2014	EX-10.26	LEASE AGREEMENT RP GATEWAY, LLC, A GEORGIA LIMITED LIABILITY COMPANY SYNAGEVA BIOPHARMA CORP., A DELAWARE CORPORATION LEASE DATED OCTOBER 22, 2013 Exhibit 10.26 [*] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Securities and Exchange Commission. LEASE AGREEMENT BETWEEN RP GATEWAY, LLC, A GEORGIA LIMITED LIABILITY COMPANY “LANDLORD” AND SYNAGEVA BIOPHARMA CORP., A DELAWARE CORPORATION “TENANT” AND FOLLOWING EXHIBITS EXHIBIT “
February 26, 2014	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 20, 2014 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Comm
February 6, 2014	SC 13G/A	GEVA / Synageva Biopharma Corp / COLUMBIA WANGER ASSET MANAGEMENT LLC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* SYNAGEVA BIOPHARMA CORP. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 87159A103 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the Rule pursuant to which this Sch
February 6, 2014	EX-99.1	EXHIBIT 99.1 - JOINT FILING AGREEMENT EX-99.1 Exhibit 99.1 EXHIBIT 99.1 - JOINT FILING AGREEMENT The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the
December 9, 2013	8-K	Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 3, 2013 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commi
November 4, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-23155 SYNA
October 29, 2013	EX-99.1	SYNAGEVA BIOPHARMA™ REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 SYNAGEVA BIOPHARMA™ REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS LEXINGTON, Mass., October 29, 2013 — Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today reported third quarter 2013 financial results and provided other business updates. Synageva announces the hiring of Gregory A. Grabowski, M.D
October 29, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 29, 2013 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commi
October 24, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 22, 2013 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commi
September 27, 2013	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 v356051ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the common stock, $0.001 par value, of Synageva BioPharma Corp. is being filed with the Securities and Exchange Commission on behalf of each of them. Septe
September 27, 2013	SC 13D/A	GEVA / Synageva Biopharma Corp / BAKER JULIAN - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 8)* Under the Securities Exchange Act of 1934 Synageva BioPharma Corp. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 896263100 (CUSIP Number) Leo Kirby 667 Madison Avenue, 21st Floor New York, NY 10065 (212) 339-5633 (Name, Address and Telephone Number of Pe
September 25, 2013	EX-99.1	September 23, 2013 EX-99.1 Exhibit 99.1 September 23, 2013 Synageva BioPharma™ Announces a 2.75 Million Share Proposed Public Offering of its Common Stock LEXINGTON, Mass.—(BUSINESS WIRE)—Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced that it intends to offer for sale 2.75 million shares of its common stock in an unde
September 25, 2013	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 23, 2013 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Com
September 25, 2013	EX-1.1	2,750,000 Shares Synageva BioPharma Corp. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 2,750,000 Shares Synageva BioPharma Corp. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT September 24, 2013 September 24, 2013 Goldman, Sachs & Co. 200 West Street New York, New York 10282 Ladies and Gentlemen: Synageva BioPharma Corp., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the
September 25, 2013	EX-99.2	SYNAGEVA BIOPHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK EX-99.2 Exhibit 99.2 SYNAGEVA BIOPHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK LEXINGTON, Mass., September 24, 2013 — Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the pricing of its previously announced underwritten public offering of common stock consisting of 2.75 million shares
September 25, 2013	424B5	CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0. Prospectus Supplement Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0.
September 23, 2013	424B5	Subject to completion, dated September 23, 2013 424(b)(5) Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed.
September 10, 2013	EX-99.1	EXHIBIT 99.1 - JOINT FILING AGREEMENT EX-99.1 Exhibit 99.1 EXHIBIT 99.1 - JOINT FILING AGREEMENT The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the
September 10, 2013	SC 13G/A	GEVA / Synageva Biopharma Corp / COLUMBIA WANGER ASSET MANAGEMENT LLC - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* SYNAGEVA BIOPHARMA CORP. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 87159A103 (CUSIP Number) August 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the Rule pursuant to which this Sched
August 9, 2013	CORRESP	- Correspondence August 9, 2013 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N.
August 7, 2013	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-23155 SYNAGEVA
August 5, 2013	EX-10.1	EMPLOYMENT AGREEMENT EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into by and between Synageva BioPharma Corp. (the “Company”), a Delaware corporation with its principal place of business at 33 Hayden Ave, Lexington, Massachusetts, and Alicia Secor of Hingham, MA (the “Executive”), effective as of August 12, 2013 (the “Effective Date”). WHEREAS, the operatio
August 5, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 5, 2013 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commiss
August 5, 2013	EX-99.1	SYNAGEVA BIOPHARMA™ REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS AND ANNOUNCES APPOINTMENT OF CHIEF OPERATING OFFICER Exhibit 99.1 SYNAGEVA BIOPHARMA™ REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS AND ANNOUNCES APPOINTMENT OF CHIEF OPERATING OFFICER LEXINGTON, Mass., August 5, 2013 — Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today reported second quarter 2013 financial results and provided other business updates. Synageva appo
July 11, 2013	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the common stock, $0.001 par value, of Synageva BioPharma Corp. is being filed with the Securities and Exchange Commission on behalf of each of them. July 11, 2013 BAKER BROS. ADVISORS LP By: Bake
July 11, 2013	SC 13D/A	GEVA / Synageva Biopharma Corp / BAKER JULIAN - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 7)* Under the Securities Exchange Act of 1934 Synageva BioPharma Corp. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 896263100 (CUSIP Number) Leo Kirby 667 Madison Avenue, 21st Floor New York, NY 10065 (212) 339-5633 (Name, Address and Telephone Number of Pe
July 10, 2013	CORRESP	- Response Letter July 10, 2013 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N.
July 2, 2013	CORRESP	- Correspondence July 2, 2013 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Jim B. Rosenberg Re: Synageva BioPharma Corp. Form 10-K for the Fiscal Year Ended December 31, 2012 Filed March 14, 2013 File No. 000-23155 Ladies and Gentlemen: Synageva BioPharma Corp. (the “Company”) confirms that it is in receipt of a comment le
June 26, 2013	S-8	- FORM S-8 Form S-8 As filed with the Securities and Exchange Commission on June 26, 2013 Registration No.
June 26, 2013	EX-4.3	SYNAGEVA BIOPHARMA CORP. (f/k/a AviGenics, inc.) 2005 STOCK PLAN EX-4.3 Exhibit 4.3 SYNAGEVA BIOPHARMA CORP. (f/k/a AviGenics, inc.) 2005 STOCK PLAN 1. Purposes of the Plan. The purposes of this 2005 Stock Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees and Consultants and to promote the success of the Company’s business. Options granted under the Plan may be I
June 10, 2013	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 6, 2013 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commissio
May 17, 2013	CORRESP	- Correspondence May 17, 2013 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N.
May 7, 2013	EX-99.1	SYNAGEVA BIOPHARMA™ REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 SYNAGEVA BIOPHARMA™ REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS LEXINGTON, Mass., May 7, 2013 — Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today reported first quarter 2013 financial results and provided other general business updates. First Quarter 2013 Financial Results For the quarter en
May 7, 2013	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-23155 SYNAGEVA
May 7, 2013	EX-10.3	LEASE 33 HAYDEN AVENUE LEXINGTON, MASSACHUSETTS Lease Dated January 15, 2013 Exhibit 10.3 LEASE 33 HAYDEN AVENUE LEXINGTON, MASSACHUSETTS Lease Dated January 15, 2013 THIS INSTRUMENT IS AN INDENTURE OF LEASE in which the Landlord and the Tenant are the parties hereinafter named, and which relates to space in a certain building (the “Building”) known as, and with an address at, 33 Hayden Avenue, Lexington, Massachusetts 02421. The parties to this Indenture of Lease hereby a
May 7, 2013	EX-10.2	EXCLUSIVE SUBLICENSE AGREEMENT Exhibit 10.2 Execution Version EXCLUSIVE SUBLICENSE AGREEMENT THIS EXCLUSIVE SUBLICENSE AGREEMENT (the “Agreement”) is made and effective as of April 5, 2013 (the “Effective Date”) by and between Shire AG, a company organized under the laws of Switzerland, having a principal place of business at Business Park Terre-Bonne, Bâtiment A1, CH. De Terre Bonne 1,1262 Eysins, Switzerland (“Shire”), and Sy
May 7, 2013	EX-10.1	BIOPROCESSING SERVICES AGREEMENT EXECUTION COPY Exhibit 10.1 BIOPROCESSING SERVICES AGREEMENT This Bioprocessing Services Agreement dated January 22, 2013 (this ?Agreement?) between Synageva BioPharma Corp., a Delaware corporation (?Sponsor?) having its principal place of business at 128 Spring Street, Suite 520, Lexington, Massachusetts 02421 and FUJIFILM Diosynth Biotechnologies U.S.A., Inc., a Delaware corporation (?Diosynth?)
May 7, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 7, 2013 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commission File Num
April 22, 2013	DEF 14A	- DEFINITIVE PROXY STATEMENT Definitive Proxy Statement SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.
April 8, 2013	8-K	Entry into a Material Definitive Agreement, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 5, 2013 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commissi
March 14, 2013	EX-21.1	Jurisdiction of Organization Exhibit 21.1 Subsidiary Jurisdiction of Organization Abbey BioPharma Corp. Delaware Synageva BioPharma Ltd United Kingdom Synageva Securities Corp. Massachusetts
March 14, 2013	10-K	Annual Report - FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified
March 14, 2013	EX-10.19	EMPLOYMENT AGREEMENT Exhibit 10.19 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made and entered into by and between Synageva BioPharma Corp. (the ?Company?), a Delaware corporation with its principal place of business at 128 Spring Street, Suite 520, Lexington, Massachusetts, and Glen Williams of Waltham, MA (the ?Executive?), effective as of September 24, 2012 (the ?Effective Date?). WHEREAS,
March 11, 2013	EX-99.1	SYNAGEVA BIOPHARMA™ REPORTS 2012 FULL YEAR FINANCIAL RESULTS EX-99.1 2 d497490dex991.htm EX-99.1 Exhibit 99.1 SYNAGEVA BIOPHARMA™ REPORTS 2012 FULL YEAR FINANCIAL RESULTS LEXINGTON, Mass., March 11, 2013 — Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today reported 2012 full year financial results and provided 2013 financial guidance. Synageva’s management
March 11, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 11, 2013 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commiss
February 15, 2013	SC 13G/A	GEVA / Synageva Biopharma Corp / TULLIS DICKERSON CAPITAL FOCUS II, L.P. - SCHEDULE 13G AMENDMENT Passive Investment Schedule 13G Amendment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 15, 2013	EX-99.1	JOINT FILING AGREEMENT EX-99.1 Exhibit 99.1 CUSIP No.: 87159A 103 JOINT FILING AGREEMENT Joint Filing Agreement, dated as of February 1, 2012, is by and among James L.L. Tullis, Tullis-Dickerson Capital Focus II, L.P., Tullis-Dickerson Partners II, L.L.C., TD Lighthouse Capital Fund, L.P., TD Javelin Capital Fund II, L.P. and TD II Regional Partners, Inc. (the “TD Filers”). Each of the TD Filers may be required to file
February 14, 2013	SC 13G	GEVA / Synageva Biopharma Corp / COLUMBIA WANGER ASSET MANAGEMENT LLC - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* SYNAGEVA BIOPHARMA CORP. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 87159A103 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the Rule pursuant to which this Schedu
January 22, 2013	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 15, 2013 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commission Fil
January 10, 2013	SC 13D/A	GEVA / Synageva Biopharma Corp / BAKER JULIAN - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 6)* Under the Securities Exchange Act of 1934 Synageva BioPharma Corp. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 896263100 (CUSIP Number) Leo Kirby 667 Madison Avenue, 21st Floor New York, NY 10065 (212) 339-5633 (Name, Address and Telephone Number of Pe
January 10, 2013	EX-99.1	JOINT FILING AGREEMENT EX-99.1 3 v331756ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the common stock, $0.001 par value, of Synageva BioPharma Corp. is being filed with the Securities and Exchange Commission on behalf of each of them. Janua
January 10, 2013	EX-10.1	FORM OF LOCK-UP LETTER January 2, 2013 EXHIBIT 10.1 FORM OF LOCK-UP LETTER January 2, 2013 Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 Ladies and Gentlemen: The undersigned understands that Morgan Stanley & Co. LLC (“Morgan Stanley”) proposes to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Synageva BioPharma Corp., a Delaware corporation (the “Company”), providing for the public offering (the “
January 4, 2013	424B5	CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2)(3) Common Stock, par value Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2)(3) Common Stock, par value $0.
January 4, 2013	EX-99.2	SYNAGEVA BIOPHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK Press Release Exhibit 99.2 SYNAGEVA BIOPHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK LEXINGTON, Mass., January 3, 2013 — Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced the pricing of its previously announced underwritten public offering of common stock consisting of 2,
January 4, 2013	EX-1.1	2,150,000 Shares Synageva BioPharma Corp. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT EX-1.1 2 d461409dex11.htm UNDERWRITING AGREEMENT Exhibit 1.1 Execution Version 2,150,000 Shares Synageva BioPharma Corp. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT January 3, 2013 January 3, 2013 Morgan Stanley & Co. LLC J.P. Morgan Securities LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Ladies and Gentlemen: Synageva BioPharma Corp., a Delaware corp
January 4, 2013	FWP	2,150,000 Shares of Common Stock Free Writing Prospectus January 3, 2012 Filed Pursuant to Rule 433 Issuer Free Writing Prospectus Registration No.
January 4, 2013	EX-99.1	SYNAGEVA BIOPHARMA ANNOUNCES $80 MILLION PROPOSED PUBLIC OFFERING OF COMMON STOCK Press Release Exhibit 99.1 SYNAGEVA BIOPHARMA ANNOUNCES $80 MILLION PROPOSED PUBLIC OFFERING OF COMMON STOCK LEXINGTON, Mass., January 3, 2013 — Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced that it has commenced a $80 million underwritten public offering of shares of its common st
January 4, 2013	8-K	Financial Statements and Exhibits, Other Events 8-K 1 d461409d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 3, 2013 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of I
January 3, 2013	S-3ASR	- S-3ASR S-3ASR Table of Contents As filed with the Securities and Exchange Commission on January 3, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
January 3, 2013	424B5	Subject to completion, dated January 3, 2013 424(b)(5) Table of Contents Filed pursuant to Rule 424(b)(5) Registration No.: 333-185856 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale
December 17, 2012	8-K	Other Events - FORM 8-K FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 17, 2012 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Comm
December 7, 2012	S-8	- FORM S-8 Form S-8 As filed with the Securities and Exchange Commission on December 7, 2012 Registration No.
December 7, 2012	EX-4.3	SYNAGEVA BIOPHARMA CORP. (f/k/a AviGenics, inc.) 2005 STOCK PLAN Synageva BioPharma Corp 2005 Stock Plan, as amended Exhibit 4.3 SYNAGEVA BIOPHARMA CORP. (f/k/a AviGenics, inc.) 2005 STOCK PLAN 1. Purposes of the Plan. The purposes of this 2005 Stock Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees and Consultants and to promote the success of the Company’s busi
December 7, 2012	EX-4.3	SYNAGEVA BIOPHARMA CORP. EMPLOYEE STOCK PURCHASE PLAN Synageva BioPharma Corp Employee Stock Purchase Plan Exhibit 4.3 SYNAGEVA BIOPHARMA CORP. EMPLOYEE STOCK PURCHASE PLAN SECTION 1. PURPOSE OF PLAN The Synageva BioPharma Corp. Employee Stock Purchase Plan (the “Plan”) shall become effective on the date that the Plan is approved by the stockholders of Synageva BioPharma Corp. (“Synageva”, f/k/a Trimeris, Inc.). The Plan is intended to enable eligibl
December 7, 2012	S-8	- FORM S-8 Form S-8 As filed with the Securities and Exchange Commission on December 7, 2012 Registration No.
November 6, 2012	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-23155 SYNA
November 6, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 6, 2012 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commi
November 6, 2012	EX-99.1	SYNAGEVA BIOPHARMA REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS - Data at NSGC meeting highlights late onset LAL Deficiency disease severity - Press Release Exhibit 99.1 SYNAGEVA BIOPHARMA REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS - Data at NSGC meeting highlights late onset LAL Deficiency disease severity - LEXINGTON, Mass., November 6, 2012 — Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today reported third quarter 2012 financial r
August 3, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 2, 2012	EX-99.1	SYNAGEVA BIOPHARMA REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS Press Release Exhibit 99.1 SYNAGEVA BIOPHARMA REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS LEXINGTON, Mass., August 2, 2012 — Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today reports second quarter 2012 financial results and announces presentations at an upcoming medical conference. Presentati
August 2, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 2, 2012 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commiss
July 20, 2012	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.001 par value, of Synageva Biopharma Corp. is being filed with the Securities and Exchange Commission on behalf of each of them. July 19, 2012 BAKER BROS. ADVISORS, LLC By: /s
July 20, 2012	SC 13D/A	GEVA / Synageva Biopharma Corp / BAKER JULIAN - FORM SC 13D/A Activist Investment SC 13D/A 1 v318958sc13da.htm FORM SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 5)* Under the Securities Exchange Act of 1934 Synageva BioPharma Corp. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 896263100 (CUSIP Number) Leo Kirby 667 Madison Avenue, 21st Floor New York, NY 10065 (212) 339-563
July 20, 2012	EX-10.1	LOCK-UP LETTER July 9, 2012 LOCK-UP LETTER July 9, 2012 Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 Ladies and Gentlemen: The undersigned understands that Morgan Stanley & Co. LLC (“Morgan Stanley”) proposes to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Synageva BioPharma Corp., a Delaware corporation (the “Company”), providing for the public offering (the “Public Offering”) by the
July 13, 2012	SC 13D/A	GEVA / Synageva Biopharma Corp / TISCH THOMAS J - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Synageva BioPharma Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 87159A 103 (CUSIP Number) Barry L. Bloom 655 Madison Avenue, 11th Floor New York, NY 10021-8043 (212) 521-2930 (Name, Address and Telephone Number of Person Authorized
July 10, 2012	424B5	SYNAGEVA BIOPHARMA CORP. 2,428,000 Shares of Common Stock Final Prospectus Supplement Table of Contents Filed pursuant to Rule 424(b)(5) Registration No.
July 10, 2012	EX-99.2	SYNAGEVA BIOPHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK Press Release Exhibit 99.2 SYNAGEVA BIOPHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK LEXINGTON, Mass., July 10, 2012 — Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced the pricing of its previously announced underwritten public offering of common stock consisting of 2,42
July 10, 2012	EX-1.1	2,428,000 Shares Synageva BioPharma Corp. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT Underwriting Agreement Exhibit 1.1 2,428,000 Shares Synageva BioPharma Corp. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT July 10, 2012 July 10, 2012 Morgan Stanley & Co. LLC J.P. Morgan Securities LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Ladies and Gentlemen: Synageva BioPharma Corp., a Delaware corporation (the “Company”), proposes to issue and s
July 10, 2012	EX-99.1	SYNAGEVA BIOPHARMA ANNOUNCES $80 MILLION PROPOSED PUBLIC OFFERING OF COMMON STOCK Press Release Exhibit 99.1 SYNAGEVA BIOPHARMA ANNOUNCES $80 MILLION PROPOSED PUBLIC OFFERING OF COMMON STOCK LEXINGTON, Mass., July 9, 2012 — Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced that it has commenced a $80 million underwritten public offering of shares of its common stock
July 10, 2012	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 10, 2012 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commissi
July 9, 2012	SC 13D/A	GEVA / Synageva Biopharma Corp / New Leaf Ventures II, L.P. - SCHEDULE 13D/A Activist Investment Schedule 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Synageva BioPharma Corp. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87159A 103 (CUSIP Number) Craig L. Slutzkin New Leaf Venture Management II, L.L.C., Times Square Tower 7 Times Square, Suite
July 9, 2012	424B5	Subject to completion, dated July 9, 2012 Prospectus Supplement Table of Contents Filed pursuant to Rule 424(b)(5) Registration No.
July 6, 2012	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 6, 2012 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commission File Nu
July 6, 2012	EX-99.3	UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 2011 Unaudited Pro Forma Condensed Combined Statement of Operations of Synageva Exhibit 99.
July 6, 2012	EX-99.2	PART I. FINANCIAL INFORMATION Trimeris, Inc. CONDENSED BALANCE SHEETS (in thousands, except per share amounts) Unaudited Condensed Financial Statements of Trimeris Exhibit 99.2 PART I. FINANCIAL INFORMATION Trimeris, Inc. CONDENSED BALANCE SHEETS (in thousands, except per share amounts) (unaudited) Item 1. Financial Statements September 30, 2011 December 31, 2010 Assets Current assets: Cash and cash equivalents $ 52,388 $ 45,164 Accounts receivable – Roche 2,047 2,458 Taxes receivable 1,136 1,214 Deferred
July 6, 2012	EX-99.1	Report of Independent Registered Public Accounting Firm Audited Financial Statements of Trimeris Exhibit 99.1 Report of Independent Registered Public Accounting Firm The Board of Directors and Shareholders of Trimeris, Inc. We have audited the accompanying balance sheets of Trimeris, Inc. as of December 31, 2010 and 2009, and the related statements of operations, stockholders’ equity, and cash flows for the years then ended. These financial statements
June 28, 2012	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 27, 2012 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commissi
June 25, 2012	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 21, 2012 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commissi
June 25, 2012	EX-99.1	SYNAGEVA BIOPHARMA ANNOUNCES SBC-102 DATA AT UPCOMING SSIEM MEETING - SBC-102 continues to improve disease-related parameters in adults with late onset LAL Deficiency - Press Release Exhibit 99.1 SYNAGEVA BIOPHARMA ANNOUNCES SBC-102 DATA AT UPCOMING SSIEM MEETING - SBC-102 continues to improve disease-related parameters in adults with late onset LAL Deficiency - LEXINGTON, Mass., June 21, 2012 — Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced accept
May 23, 2012	S-3	- FORM S-3 Form S-3 Table of Contents As filed with the Securities and Exchange Commission on May 23, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 9, 2012	EX-10.1	Cytovance Biologics, Inc. Biopharmaceutical Services Agreement Synageva BioPharma Corp. Exhibit 10.1 Cytovance Biologics, Inc. Biopharmaceutical Services Agreement for Synageva BioPharma Corp. This Biopharmaceutical Services Agreement (the “Agreement”) dated Feb. 27, 2012 (the “Effective Date”) between Synageva BioPharma Corp., (“Synageva”) a company having a place of business at 128 Spring Street, Suite 520, Lexington, MA 02421 and Cytovance Biologics, Inc. a Delaware corporation (“
May 9, 2012	10-Q	Quarterly Report - FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 9, 2012	EX-10.2	AMENDMENT TO THE BIOPHARMACEUTICAL SERVICES AGREEMENT Exhibit 10.2 AMENDMENT TO THE BIOPHARMACEUTICAL SERVICES AGREEMENT THIS AMENDMENT (“Amendment”) effective as of April 27, 2012 (“Effective Date”), is between Synageva BioPharma Corp., a Delaware corporation with a principal office at 128 Spring Street, Suite 520, Lexington MA 02421 (phone: 781-357-9900; fax: 781-357-9901) (“Synageva”) and Cytovance Biologics, Inc. a Delaware corporation having its
May 4, 2012	SC 13D/A	GEVA / Synageva Biopharma Corp / BAKER JULIAN - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 4)* Under the Securities Exchange Act of 1934 Synageva BioPharma Corp. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 896263100 (CUSIP Number) Leo Kirby 667 Madison Avenue, 21st Floor New York, NY 10065 (212) 339-5633 (Name, Address and Telephone Number of Pe
April 27, 2012	DEF 14A	- NOTICE AND PROXY STATEMENT SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.
April 24, 2012	10-K/A	Annual Report - AMENDMENT NO.1 TO FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specifie
March 28, 2012	SC 13D/A	GEVA / Synageva Biopharma Corp / New Leaf Ventures II, L.P. - SCHEDULE 13D AMENDMENT NO. 1 Activist Investment SC 13D/A 1 d324345dsc13da.htm SCHEDULE 13D AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Synageva BioPharma Corp. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87159A 103 (CUSIP Number) Craig L. Slutzkin New Leaf Venture Management II, L.L.C
March 22, 2012	EX-10.12	SYNAGEVA BIOPHARMA CORP. 2005 STOCK PLAN STOCK OPTION AGREEMENT Exhibit 10.12 SYNAGEVA BIOPHARMA CORP. 2005 STOCK PLAN STOCK OPTION AGREEMENT 1. Grant of Option. Synageva BioPharma Corp., a Delaware corporation (the ?Company?), hereby grants to [Name] (?Optionee?), an option (the ?Option?) to purchase the total number of shares of Common Stock (the ?Shares?) set forth in the Notice of Stock Option Grant (the ?Notice?), at the exercise price per Share set forth
March 22, 2012	EX-10.20	LEASE AGREEMENT Lease Agreement, Synageva BioPharma Corp. and Barrett Investment Properties, LLC Exhibit 10.20 LEASE AGREEMENT This lease is made this day of January 2012, by and between Barrett Investment Properties, LLC, a Georgia limited liability company (hereinafter called “Landlord”), and Synageva BioPharma Corp., a Delaware corporation (hereinafter called “Tenant”). WITNESSETH 1. PREMISES Landlord, for and
March 22, 2012	10-K	Annual Report - FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified
March 22, 2012	EX-21.1	Jurisdiction of Organization Exhibit 21.1 Subsidiary Jurisdiction of Organization Abbey BioPharma Corp. Delaware Synageva BioPharma Ltd United Kingdom
March 22, 2012	EX-10.19	FIRST AMENDMENT TO LEASE EX-10.19 3 d262321dex1019.htm FIRST AMENDMENT TO LEASE AGREEMENT DATED NOVEMBER 29, 2011 Exhibit 10.19 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE is made this 29th day of November, 2011, by and between ONE LEDGEMONT LLC (“Landlord”) and SYNAGEVA BIOPHARMA CORP. (“Tenant”). BACKGROUND: A. Reference is made to a certain Lease dated April 8, 2010, by and between Landlord and Tenant (the “
March 15, 2012	EX-99.1	SYNAGEVA BIOPHARMA REPORTS 2011 FULL YEAR FINANCIAL RESULTS - Strengthened balance sheet enables a focus on key objectives- -Adult LAL Deficiency patients continue to enroll into extension study - Press Release Exhibit 99.1 SYNAGEVA BIOPHARMA REPORTS 2011 FULL YEAR FINANCIAL RESULTS - Strengthened balance sheet enables a focus on key objectives- -Adult LAL Deficiency patients continue to enroll into extension study - LEXINGTON, Mass., March 15, 2012 — Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare diso
March 15, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 15, 2012 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Commiss
March 5, 2012	8-K	Entry into a Material Definitive Agreement - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 28, 2012 SYNAGEVA BIOPHARMA CORP. (Exact Name of Registrant as Specified in Charter) Delaware 0-23155 56-1808663 (State or Other Jurisdiction of Incorporation) (Comm
February 17, 2012	SC 13G/A	GEVA / Synageva Biopharma Corp / RA CAPITAL MANAGEMENT, L.P. - AMENDMENT TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Synageva BioPharma Corp. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87159A103 (CUSIP Number) February 14, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
February 14, 2012	SC 13G/A	GEVA / Synageva Biopharma Corp / RA CAPITAL MANAGEMENT, L.P. - SC 13GA Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Trimeris, Inc. (Name of Issuer) Common Shares, $0.001 par value (Title of Class of Securities) 896263100 (CUSIP Number) January 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w
February 9, 2012	EX-99.1	SYNAGEVA BIOPHARMA ANNOUNCES INTERIM DATA AT 8th ANNUAL LYSOSOMAL DISEASE NETWORK (LDN) WORLD SYMPOSIUM - SBC-102 was well tolerated and demonstrated predicted pharmacodynamic effects in a Phase I/II trial in late onset LAL Deficiency - Press Release Exhibit 99.1 SYNAGEVA BIOPHARMA ANNOUNCES INTERIM DATA AT 8th ANNUAL LYSOSOMAL DISEASE NETWORK (LDN) WORLD SYMPOSIUM - SBC-102 was well tolerated and demonstrated predicted pharmacodynamic effects in a Phase I/II trial in late onset LAL Deficiency - LEXINGTON, Mass., February 9, 2012 — Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company dev

GEVA / Synageva Biopharma Corp - Documents déposés auprès de la SEC, rapport annuel, procuration

Statistiques de base

SEC Filings

SEC Filings (Chronological Order)